Public disclosures

Smart Money

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
McCombe William D.

Chief Financial Officer · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 138886 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

2,127 shares/units

SEC 4Follow
McCombe William D.

Chief Financial Officer · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 141013 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

6,320 shares/units

SEC 4Follow
Kelliher Mike

Chief Business Officer · ARDELYX, INC.

ARDX

ARDELYX, INC.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 342341 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

2026-11-192026-11-20

7,319 shares/units

SEC 4Follow
Dols Scott V.

Director · OPAL Fuels Inc.

OPAL

OPAL Fuels Inc.

Buy
Filing details

SEC transaction code P

Class A common stock · Direct ownership · Reported balance after transaction: 327448 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging between $1.34 and $1.44. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2026-11-192026-11-20

≈ $56,834.32

40,888 shares/units

SEC 4Follow
Dols Scott V.

Director · OPAL Fuels Inc.

OPAL

OPAL Fuels Inc.

Buy
Filing details

SEC transaction code P

Class A common stock · Direct ownership · Reported balance after transaction: 286560 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging between $1.19 and $1.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2026-11-182026-11-20

≈ $55,607.68

40,888 shares/units

SEC 4Follow
Ferraro Christopher C

President and CIO · Galaxy Digital Inc.

GLXY

Galaxy Digital Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Options · Derivative security · Direct ownership · Reported balance after transaction: 700000 · These options are vested and exercisable until March 29, 2028.

2026-11-202026-11-20

100,000 shares/units

SEC 4Follow
Ferraro Christopher C

President and CIO · Galaxy Digital Inc.

GLXY

Galaxy Digital Inc.

Exercise or conversion
Filing details

SEC transaction code M

Class A Common Stock · Direct ownership · Reported balance after transaction: 1158292 · Represents shares of Class A common stock acquired with cash upon the exercise of 100,000 stock options now held. · Includes 281,185 shares of Class A common stock to be delivered in settlement of restricted stock units ("RSUs"), subject to continued service through the applicable vesting date. · Each RSU represents the right to receive one share of Class A common stock.

2026-11-202026-11-20

100,000 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 762842 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.

2026-11-182026-11-20

57,212 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 270692 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.

2026-11-182026-11-20

29,002 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 117873 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.

2026-11-182026-11-20

22,100 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 15713 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.

2026-11-182026-11-20

11,781 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5633865 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

22,513 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5656378 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

57,212 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5599166 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

11,413 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5610579 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

29,002 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5581577 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

8,697 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5590274 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

22,100 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5568174 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

4,636 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5572810 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

11,781 shares/units

SEC 4Follow
RAAB MICHAEL

President & CEO · Director · ARDELYX, INC.

ARDX

ARDELYX, INC.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 1567416 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. · Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on August 31, 2026.

2026-11-192026-11-20

55,376 shares/units

SEC 4Follow
Li Jeffrey K

SVP and Secretary · Keysight Technologies, Inc.

KEYS

Keysight Technologies, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 44327.952 · Securities delivered or withheld for tax or exercise payment · The reporting person surrendered 972 shares to Keysight to satisfy tax liability on the release of restricted shares in accordance with Rule 16b-3.

2026-11-192026-11-20

972 shares/units

SEC 4Follow
Li Jeffrey K

SVP and Secretary · Keysight Technologies, Inc.

KEYS

Keysight Technologies, Inc.

Equity grant or award
Filing details

SEC transaction code A

Common Stock · Direct ownership · Reported balance after transaction: 45299.952 · Common stock underlying restricted stock units ("RSUs") granted on November 18, 2026, pursuant to the Keysight 2014 Equity and Incentive Compensation Plan. The RSUs vest in equal installments on each of the first four anniversaries of the grant date.

2026-11-182026-11-20

5,175 shares/units

SEC 4Follow
Li Jeffrey K

SVP and Secretary · Keysight Technologies, Inc.

KEYS

Keysight Technologies, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 40124.952 · Securities delivered or withheld for tax or exercise payment · The reporting person surrendered 8,513 shares to Keysight to satisfy the tax liability on the release of the Long-Term Performance shares in accordance with Rule 16b-3.

2026-11-182026-11-20

8,513 shares/units

SEC 4Follow
Li Jeffrey K

SVP and Secretary · Keysight Technologies, Inc.

KEYS

Keysight Technologies, Inc.

Equity grant or award
Filing details

SEC transaction code A

Common Stock · Direct ownership · Reported balance after transaction: 48637.952 · On November 18, 2026, pursuant to the Keysight Technologies, Inc. Long-Term Performance Program, 17,169 shares of common stock of Keysight Technologies, Inc. were awarded to the reporting person.

2026-11-182026-11-20

17,169 shares/units

SEC 4Follow
Dougherty Neil

EVP and CFO · Keysight Technologies, Inc.

KEYS

Keysight Technologies, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 137068.541 · Securities delivered or withheld for tax or exercise payment · The reporting person surrendered 1,754 shares to Keysight to satisfy tax liability on the release of restricted shares in accordance with Rule 16b-3.

2026-11-192026-11-20

1,754 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement